El interés en corto de Balchem da a los inversores una idea del grado en que los inversores apuestan por la caída de las acciones de Balchem. Los datos de interés en corto se actualizan cada dos semanas.

Balchem (NASDAQ:BCPC) Bolsa, Informe de interés en corto

Balchem

Balchem Corp is engaged in the development, manufacture, and marketing of specialty performance ingredients and products for various industries. The company's reportable segments are; Human Nutrition and Health, which generates maximum revenue, and provides human-grade choline nutrients and mineral amino acid chelated products through this segment for nutrition and health applications; Animal Nutrition and Health, which provides nutritional products derived from its microencapsulation and chelation technologies in addition to the essential nutrient choline chloride; and the Specialty Products segment includes re-packaging and distributing several performance gases and chemicals. Geographically, the company derives its key revenue from the United States and the rest from foreign countries.

Brunswick Corporation 6.375% Notes due 2049

Balchem Corp

HC Wainwright &amp; Co. analyst Raghuram Selvaraju maintains Balchem (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCPC#NASDAQ">BCPC</a>) with a Buy and lowers the price target from $190 to $180.

News

Price Target

Analyst Ratings

BCPC

HC Wainwright & Co. Maintains Buy on Balchem, Lowers Price Target to $180

WIIM

Balchem shares are trading lower. The company reported Q1 financial results.

Balchem (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCPC#NASDAQ">BCPC</a>) reported quarterly earnings of $1.22 per share which met the analyst consensus estimate. This is a 18.45 percent increase over earnings of $1.03 per share from the same period last year. The company reported quarterly sales of $250.52 million which beat the analyst consensus estimate of $245.70 million by 1.96 percent. This is a 4.53 percent increase over sales of $239.66 million the same period last year.

Earnings

Earnings Beats

Balchem Q1 Adj. EPS $1.22, Inline, Sales $250.52M Beat $245.70M Estimate

ADXN

ALEX

ALLE

AMAL

AMBP

APOG

APPF

BAFN

BELFA

BELFB

BFST

BHLB

BWMX

CBRE

CIVB

CMCSA

CNOB

COUR

CUBI

CURB

DAIO

DGICA

DGICB

ERIE

FARO

FBIZ

FCFS

FCNCA

FFBC

FRME

GBCI

GILD

GLPI

GNFT

GOOG

GOOGL

HELE

HFWA

IBCP

INDV

INTC

ITGR

KNSL

KRNY

LADR

LYTS

MBLY

MGRC

MMSI

MOFG

Earnings Scheduled For April 24, 2025

Balchem (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCPC#NASDAQ">BCPC</a>) will release its quarterly earnings report on Thursday, 2025-04-24. Here's a brief overview for investors ahead of the announcement.
Analysts anticipate Balchem to report an earnings per share (EPS) of $1.22.
Anticipation surrounds Balchem's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.
New investors should understand that while earnings performance is important, market reactions are often driven by guidance.
<h3>Past Earnings Performance</h3>
During the last quarter, the company reported an EPS beat by $0.02, leading to a 0.0% drop in the share price on the subsequent day.
Here's a look at Balchem's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>1.11</td>
<td>1.11</td>
<td>1.03</td>
<td>0.99</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>1.13</td>
<td>1.13</td>
<td>1.09</td>
<td>1.03</td>
</tr>
<tr>
<td>Price Change %</td>
<td>1.0%</td>
<td>3.0%</td>
<td>3.0%</td>
<td>3.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1745427752_0.png" alt="eps graph" />
<h3>Stock Performance</h3>
Shares of Balchem were trading at $157.5 as of April 22. Over the last 52-week period, shares are up 14.44%. Given that these returns are generally positive, long-term shareholders should be satisfied going into this earnings release. 
<a href="https://www.benzinga.com/quote/BCPC/earnings">To track all earnings releases for Balchem visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

What's Next: Balchem's Earnings Preview

HC Wainwright &amp; Co. analyst Raghuram Selvaraju reiterates Balchem (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCPC#NASDAQ">BCPC</a>) with a Buy and maintains $190 price target.

Reiteration

HC Wainwright & Co. Reiterates Buy on Balchem, Maintains $190 Price Target

General

Balchem Corporation shares are trading higher after the company reported better-than-expected Q4 financial results.

Balchem (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCPC#NASDAQ">BCPC</a>) reported quarterly earnings of $1.13 per share which beat the analyst consensus estimate of $1.10 by 2.73 percent. This is a 18.95 percent increase over earnings of $0.95 per share from the same period last year. The company reported quarterly sales of $240.00 million which beat the analyst consensus estimate of $239.96 million by 0.02 percent. This is a 4.94 percent increase over sales of $228.70 million the same period last year.

Balchem Q4 2024 Adj EPS $1.13 Beats $1.10 Estimate, Sales $240.00M Beat $239.96M Estimate

<h3>Companies Reporting Before The Bell</h3>
• Brady (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRC#NYSE">BRC</a>) is estimated to report quarterly earnings at $1.03 per share on revenue of $359.20 million. 
• SES AI (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SES#NYSE">SES</a>) is projected to report quarterly earnings at $0.20 per share on revenue of $361.90 million. 
• Atmus Filtration Techs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ATMU#NYSE">ATMU</a>) is likely to report quarterly earnings at $0.53 per share on revenue of $399.24 million. 
• AdvanSix (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ASIX#NYSE">ASIX</a>) is expected to report quarterly loss at $0.37 per share on revenue of $377.15 million. 
• Vipshop Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VIPS#NYSE">VIPS</a>) is likely to report quarterly earnings at $0.72 per share on revenue of $4.42 billion. 
• Arbor Realty Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABR#NYSE">ABR</a>) is projected to report quarterly earnings at $0.39 per share on revenue of $86.28 million. 
• Oil States International (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OIS#NYSE">OIS</a>) is expected to report quarterly earnings at $0.05 per share on revenue of $173.33 million. 
• United States Cellular (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USM#NYSE">USM</a>) is estimated to report quarterly earnings at $1.70 per share on revenue of $964.70 million. 
• Telephone and Data (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDS#NYSE">TDS</a>) is likely to report quarterly loss at $0.23 per share on revenue of $1.26 billion. 
• Balchem (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCPC#NASDAQ">BCPC</a>) is projected to report quarterly earnings at $1.11 per share on revenue of $239.96 million. 
• Federal Agricultural (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AGM#NYSE">AGM</a>) is expected to report quarterly earnings at $4.17 per share on revenue of $92.81 million. 
• Uniti Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UNIT#NASDAQ">UNIT</a>) is projected to report quarterly earnings at $0.33 per share on revenue of $295.37 million. 
• Sunstone Hotel Invts (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHO#NYSE">SHO</a>) is estimated to report quarterly earnings at $0.14 per share on revenue of $215.79 million. 
• TXNM Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TXNM#NYSE">TXNM</a>) is likely to report quarterly earnings at $0.30 per share on revenue of $496.05 million. 
<h3>Companies Reporting After The Bell</h3>
• Hawaiian Electric Indus (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HE#NYSE">HE</a>) is expected to report quarterly earnings at $0.34 per share on revenue of $1.16 billion. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ASIX

ATMU

TXNM

UNIT

VIPS

Earnings Scheduled For February 21, 2025

HC Wainwright &amp; Co. analyst Raghuram Selvaraju maintains Balchem (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCPC#NASDAQ">BCPC</a>) with a Buy and raises the price target from $185 to $190.

HC Wainwright & Co. Maintains Buy on Balchem, Raises Price Target to $190

Balchem shares are trading higher after the company reported better-than-expected Q3 adjusted EPS results.

Balchem (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCPC#NASDAQ">BCPC</a>) reported quarterly earnings of $1.13 per share which beat the analyst consensus estimate of $1.11 by 1.8 percent. This is a 8.65 percent increase over earnings of $1.04 per share from the same period last year. The company reported quarterly sales of $239.94 million which missed the analyst consensus estimate of $241.93 million by 0.82 percent. This is a 4.35 percent increase over sales of $229.95 million the same period last year.

Earnings Misses

Balchem Q3 Adj $1.13 Beats $1.11 Estimate, Sales $239.94M Miss $241.93M Estimate

Balchem (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCPC#NASDAQ">BCPC</a>) will release its quarterly earnings report on Friday, 2024-10-25. Here's a brief overview for investors ahead of the announcement.
Analysts anticipate Balchem to report an earnings per share (EPS) of $1.11.
The market awaits Balchem's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.
It's important for new investors to understand that guidance can be a significant driver of stock prices.
<h3>Historical Earnings Performance</h3>
The company's EPS beat by $0.06 in the last quarter, leading to a 0.0% drop in the share price on the following day.
Here's a look at Balchem's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
<th>Q3 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>1.03</td>
<td>0.99</td>
<td>0.93</td>
<td>0.97</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>1.09</td>
<td>1.03</td>
<td>0.95</td>
<td>1.04</td>
</tr>
<tr>
<td>Price Change %</td>
<td>3.0%</td>
<td>3.0%</td>
<td>2.0%</td>
<td>-5.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1729782112_0.png" alt="eps graph" />
<h3>Performance of Balchem Shares</h3>
Shares of Balchem were trading at $166.76 as of October 23. Over the last 52-week period, shares are up 44.86%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<a href="https://www.benzinga.com/quote/BCPC/earnings">To track all earnings releases for Balchem visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings Outlook For Balchem

HC Wainwright &amp; Co. analyst Raghuram Selvaraju maintains Balchem (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCPC#NASDAQ">BCPC</a>) with a Buy and raises the price target from $170 to $185.

HC Wainwright & Co. Maintains Buy on Balchem, Raises Price Target to $185

When it comes to short-term investing or trading, they say &quot;the trend is your friend.&quot; And there&#39;s no denying that this is the most profitable strategy. But making sure of the sustainability of a trend to profit from it is easier said than done.
The trend often reverses before exiting the trade, leading to a short-term capital loss for investors. So, for a profitable trade, one should confirm factors such as sound fundamentals, positive earnings estimate revisions, etc. that could keep the momentum in the stock alive.
Our &quot;Recent Price Strength&quot; screen, which is created on a unique short-term trading strategy, could be pretty useful in this regard. This predefined screen makes it really easy to shortlist the stocks that have enough fundamental strength to maintain their recent uptrend. Also, the screen passes only the stocks that are trading in the upper portion of their 52-week high-low range, which is usually an indicator of bullishness.
Blachem (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bcpc#NASDAQ">BCPC</a>) is one of the several suitable candidates that passed through the screen. Here are the key reasons why it could be a profitable bet for &quot;trend&quot; investors.
A solid price increase over a period of 12 weeks reflects investors&#39; continued willingness to pay more for the potential upside in a stock. BCPC is quite a good fit in this regard, gaining 20.2% over this period.
However, it&#39;s not enough to look at the price change for around three months, as it doesn&#39;t reflect any trend reversal that might have happened in a shorter time frame. It&#39;s important for a potential winner to maintain the price trend. A price increase of 17.4% over the past four weeks ensures that the trend is still in place for the stock of this chemical company.
Moreover, BCPC is currently trading at 97.5% of its 52-week High-Low Range, hinting that it can be on the verge of a breakout.
Looking at the fundamentals, the stock currently carries a Zacks Rank #1 (Strong Buy), which means it is in the top 5% of more than the 4,000 stocks that we rank based on trends in earnings estimate revisions and EPS surprises -- the key factors that impact a stock&#39;s near-term price movements.
The Zacks Rank stock-rating system, which uses four factors related to earnings estimates to classify stocks into five groups, ranging from Zacks Rank #1 (Strong Buy) to Zacks Rank #5 (Strong Sell), has an impressive externally-audited track record, with Zacks Rank #1 stocks generating an average annual return of +25% since 1988.
Another factor that confirms the company&#39;s fundamental strength is its Average Broker Recommendation of #1 (Strong Buy). This indicates that the brokerage community is highly optimistic about the stock&#39;s near-term price performance.
So, the price trend in BCPC may not reverse anytime soon.
<a href="https://www.zacks.com/stock/news/2310616/blachem-bcpc-is-on-the-move-here-s-why-the-trend-could-be-sustainable?cid=CS-BENZ-FT-tale_of_the_tape|recent_price_strength_screen-2310616">To read this article on Zacks.com click here.</a>

Markets

Trading Ideas

Blachem is on the Move, Here's Why the Trend Could be Sustainable

Balchem (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCPC#NASDAQ">BCPC</a>) reported quarterly earnings of $1.09 per share which beat the analyst consensus estimate of $1.03 by 5.83 percent. This is a 2.83 percent increase over earnings of $1.06 per share from the same period last year. The company reported quarterly sales of $234.08 million which missed the analyst consensus estimate of $239.69 million by 2.34 percent. This is a 1.22 percent increase over sales of $231.25 million the same period last year.

Balchem Q2 Adj $1.09 Beats $1.03 Estimate, Sales $234.08M Miss $239.69M Estimate

Avian influenza, also known as bird flu, has public health <a href="https://www.benzinga.com/news/24/07/39594907/amid-rapidly-rising-bird-flu-cases-moderna-lands-176m-worth-us-government-contract-for-vaccine">officials on alert</a> after it spread to an unprecedented number of cows in the U.S. this year and led to positive tests of the virus in four U.S. dairy workers so far this year.
A severe variant of the H5N1 strain infected animals ranging from alpacas to house cats worldwide since 2020 and caused lethal outbreaks in commercial poultry, but this is the first year it has infected cows, Reuters reported.
Humans have contracted different bird flu strains in Australia and Mexico, while different H5 subtypes have also shown up in other parts of the world including China and Cambodia.
Most of the human cases have come from exposure to poultry, live poultry markets and dairy cattle, but scientists worry the virus could mutate so it could easily spread between humans and spark a pandemic. The World Health Organization says the risk to people is low at this point, Reuters reported.
The first known bird flu cases happened in Texas in March, and now the virus has infected dairy herds in 12 states. The U.S. Agriculture Department said tests so far reveal that the virus detected in cows is the same H5N1 virus affecting wild birds and commercial poultry flocks.
Also Read: <a href="https://www.benzinga.com/general/biotech/24/06/39213667/first-human-death-from-bird-flu-strain-puts-vaccine-stocks-back-on-the-map">First Human Death From Bird Flu Strain Puts Vaccine Stocks Back On The Map</a>
The four dairy workers who have tested positive for the virus this year had mild symptoms such as conjunctivitis, or pink eye.
Michigan, which has two of the four cases infecting dairy workers, has led the nation in efforts to stop the spread of bird flu and prevent negative impacts to the state&#8217;s dairy industry. 
State restrictions include tracking who comes and goes from farms as Michigan tests more people than any of the 12 states with confirmed cases in cows, according to a Reuters survey of state health departments. 
So far this year, various forms of bird flu have been detected in 21 people worldwide, according to Reuters.
Price Action: Most companies busy developing bird-flu vaccines saw gains on Wednesday. Moderna, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) picked up 1.18% to close at $117.44, while GSK plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GSK#NYSE">GSK</a>) slipped 0.12% to $38.56 and Carlisle Companies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CSL#NYSE">CSL</a>) gained 2.28% to $416.88.
Dairy stocks and agriculture and dairy cattle exchange-traded funds gave mixed reactions. AGCO Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AGCO#NYSE">AGCO</a>) gained 0.69% to close at $94.21 on Wednesday as Aemetis, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMTX#NASDAQ">AMTX</a>) declined 3.18% to $3.35 and Balchem Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCPC#NASDAQ">BCPC</a>) picked up 0.60% to $162.89.
Invesco DB Agriculture Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DBA#NYSE">DBA</a>) declined 1.23% on Wednesday to $1.23, while First Trust Dow Jones Select MicroCap Index Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FDM#NYSE">FDM</a>) rose 1.71% to $59.51 and Invesco S&amp;P SmallCap 600 Pure Value ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RZV#NYSE">RZV</a>) improved 1.32% to $98.
<h4 class="wp-block-heading">Read Now:</h4>
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/07/39710325/investor-that-backed-moderna-raises-3-6b-for-ai-driven-biotech-ventures">Investor That Backed Moderna Raises $3.6B For AI-driven Biotech Ventures</a></li>
</ul>
Photo: Shutterstock

Health Care

ETFs

AGCO

AMTX

First Trust/First Trust Dow Jones Select MicroCap Index Fund

MRNA

Rydex ETF Trust S&P Smallcap 600 Pure Value ETF

Health Officials Keep Close Eye On Bird Flu As It Infects Cows For The First Time

As of July 9, 2024, two stocks in the materials sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the <a href="https://www.benzinga.com/topic/rsi">RSI is above 70</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>. 
Here's the latest list of major overbought players in this sector.
<h3 class="wp-block-heading">Balchem Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCPC#NASDAQ">BCPC</a>)</h3>
<ul>
<li>On May 3, Balchem posted better-than-expected first-quarter results. Ted Harris, Chairman, President and CEO of Balchem said, &#8220;The first quarter was a very good start to the year for Balchem. We delivered record net sales, adjusted EBITDA, and net earnings, as well as solid first quarter cash flows, despite the continued challenging environment in parts of our portfolio.&#8221; The company's stock gained around 6% over the past five days and has a <a href="https://www.benzinga.com/quote/BCPC">52-week high of $163.02</a>.</li>
<li>RSI Value: 70.11&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li>
<li>BCPC Price Action: Shares of Balchem gained 1.1% to close at $162.28 on Monday.</li>
</ul>
<h3 class="wp-block-heading">Anglogold Ashanti PLC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AU#NYSE">AU</a>)</h3>
<ul>
<li>On July 3, JP Morgan analyst Patrick Jones maintained Anglogold Ashanti with an Overweight and lowered the price target from $33 to $32. The company's stock gained around 25% over the past month and <a href="https://www.benzinga.com/quote/AU">has a 52-week high</a> of $29.08.</li>
<li>RSI Value: 71.29</li>
<li>AU Price Action: Shares of Anglogold Ashanti fell 1.9% to close at $28.27 on Monday.</li>
</ul>
Read More: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/07/39665755/wall-streets-most-accurate-analysts-say-buy-these-3-utilities-stocks-delivering-high-div">Wall Street&#8217;s Most Accurate Analysts Say Buy These 3 Utilities Stocks Delivering High-Dividend Yields</a>

Short Ideas

Pre-Market Outlook

Top 2 Materials Stocks You May Want To Dump This Month

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-ratings/">analyst ratings page</a>.
<ul>
<li>Wedbush raised the price target for BJ&#8217;s Restaurants, Inc.  (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BJRI#NASDAQ">BJRI</a>) from $40 to $43. Wedbush analyst Nick Setyan maintained an Outperform rating. BJ&#8217;s Restaurants shares rose 5.9% to close at $34.68 on Friday. <a href="https://www.benzinga.com/quote/BJRI/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Mizuho boosted the price target for Robinhood Markets, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOOD#NASDAQ">HOOD</a>) from $20 to $21. Mizuho analyst Dan Dolev maintained a Buy rating. Robinhood shares rose 1.9% to close at $17.95 on Friday. <a href="https://www.benzinga.com/quote/HOOD/analyst-ratings">See how other analysts view this stock.</a></li>
<li>B of A Securities cut Fox Factory Holding Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FOXF#NASDAQ">FOXF</a>) price target from $55 to $48. B of A Securities analyst Alexander Perr maintained a Neutral rating. Fox Factory shares rose 10.4% to close at $43.52 on Friday. <a href="https://www.benzinga.com/quote/FOXF/analyst-ratings">See how other analysts view this stock.</a></li>
<li>HC Wainwright &amp; Co. increased the price target for Franco-Nevada Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FNV#NYSE">FNV</a>) from $175 to $185. HC Wainwright &amp; Co. analyst Heiko Ihle maintained a Buy rating. Franco-Nevada shares rose 1.9% to close at $123.25 on Friday. <a href="https://www.benzinga.com/quote/FNV/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Baird raised Fluor Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FLR#NYSE">FLR</a>) price target from $42 to $46. Baird analyst Andrew Wittmann maintained an Outperform rating. Fluor shares fell 5.7% to close at $38.90 on Friday. <a href="https://www.benzinga.com/quote/FLR/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Piper Sandler increased Essex Property Trust, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ESS#NYSE">ESS</a>) price target from $291 to $315. Piper Sandler analyst Alexander Goldfarb maintained an Overweight rating. Essex Property Trust shares gained 0.2% to close at $250.31 on Friday. <a href="https://www.benzinga.com/quote/ESS/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>HC Wainwright &amp; Co. raised the price target for Balchem Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCPC#NASDAQ">BCPC</a>) from $167 to $170. HC Wainwright &amp; Co. analyst Raghuram Selvaraju maintained a Buy rating. Balchem shares rose 2.8% to close at $150.40 on Friday. <a href="https://www.benzinga.com/quote/BCPC/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Bernstein boosted American Airlines Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAL#NASDAQ">AAL</a>) price target from $21 to $22. Bernstein analyst David Vernon maintained an Outperform rating. American Airlines shares fell 0.1% to close at $13.85 on Friday. <a href="https://www.benzinga.com/quote/AAL/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Morgan Stanley increased Bausch + Lomb Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BLCO#NYSE">BLCO</a>) price target from $16 to $18. Morgan Stanley analyst Patrick Wood upgraded the stock from Equal-Weight to Overweight. Bausch + Lomb shares fell 1.9% to close at $13.60 on Friday. <a href="https://www.benzinga.com/quote/BLCO/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Wedbush increased Mid-America Apartment Communities, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MAA#NYSE">MAA</a>) price target from $135 to $154. Wedbush analyst Richard Anderson upgraded the stock from Neutral to Outperform. Mid-America Apartment shares rose 1% to close at $133.00 on Friday. <a href="https://www.benzinga.com/quote/MAA/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Check This Out: <a href="https://www.benzinga.com/news/24/05/38614014/coinbase-global-doordash-and-2-other-stocks-insiders-are-selling">Coinbase Global, DoorDash And 2 Other Stocks Insiders Are Selling</a>

BJRI

BLCO

FOXF

HOOD

American Airlines To Rally Around 59%? Here Are 10 Top Analyst Forecasts For Monday

HC Wainwright &amp; Co. analyst Raghuram Selvaraju maintains Balchem (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCPC#NASDAQ">BCPC</a>) with a Buy and raises the price target from $167 to $170.

HC Wainwright & Co. Maintains Buy on Balchem, Raises Price Target to $170

Press Releases

Balchem Corporation Reports Third Quarter 2024 Financial Results

Balchem Corporation to Present at Baird's 54th Annual Global Industrial Conference on November 13, 2024

Dividends

Balchem Corporation Announces Dividend

Balchem Corporation to Present at CJS Securities New Ideas for the New Year Virtual Conference on January 14, 2025

Balchem Corporation Announces Quarterly Conference Call for Fourth Quarter and Full Year 2024 Financial Results on February 21, 2025

Balchem Corporation Reports Fourth Quarter and Full Year 2024 Financial Results

Balchem Corporation to Participate in the BNP Paribas Exane 13th Consumer Ingredients Conference on March 11, 2025

Balchem Corporation Announces Quarterly Conference Call for First Quarter 2025 Financial Results on April 24, 2025

Balchem Corporation Releases 2024 Sustainability Report

Balchem Corporation Reports First Quarter 2025 Financial Results

HC Wainwright & Co.

Comments

Balchem

Interés en corto

Balchem (NASDAQ:BCPC) Bolsa, Informe de interés en corto

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL